Nica Classen

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Topics

Respiratory Syndrome Coronavirus

Sensitive Detection

Dendritic Cells

Angiotensin Converting Enzyme

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Schöfbänker, Rieke Neddermeyer, Theresa Guenther, Marlin M Mueller, Marie-Luise Romberg, Nica Classen, Marc T Hennies, Eike R Hrincius, Stephan Ludwig, Joachim E Kuehn, Eva Ulla Lorentzen
Surrogate Virus Neutralisation Test Based on Nanoluciferase-Tagged Antigens to Quantify Inhibitory Antibodies against SARS-CoV-2 and Characterise Omicron-Specific Reactivity in a Vaccination Cohort. Vaccines 11 (12) (2023)
Michael Schöfbänker, Rieke Neddermeyer, Theresa Guenther, Marlin M Mueller, Marie-Luise Romberg, Nica Classen, Marc T Hennies, Eike R Hrincius, Stephan Ludwig, Joachim E Kuehn, Eva Ulla Lorentzen
Surrogate Virus Neutralisation Test Based on Nanoluciferase-Tagged Antigens to Quantify Inhibitory Antibodies against SARS-CoV-2 and Characterise Omicron-Specific Reactivity in a Vaccination Cohort. Vaccines 11 (12) (2023)
Nica Classen, Diana Ulrich, Arne Hofemeier, Marc Tim Hennies, Wali Hafezi, Aleksandra Pettke, Marie-Luise Romberg, Eva Ulla Lorentzen, Andreas Hensel, Joachim E Kühn
Broadly Applicable, Virus-Free Dual Reporter Assay to Identify Compounds Interfering with Membrane Fusion: Performance for HSV-1 and SARS-CoV-2. Viruses 14 (7) (2022)
Fakry Fahmy Mohamed, Darisuren Anhlan, Michael Schöfbänker, André Schreiber, Nica Classen, Andreas Hensel, Georg Hempel, Wolfgang Scholz, Joachim E Kuehn, Eike R Hrincius, Stephan Ludwig
Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2. Pharmaceuticals (Basel, Switzerland) 15 (5) (2022)